UPDATE: Taglich Brothers Raises PT to $13.25 on Novadaq Technologies on Valuation
Taglich Brothers reiterated its Buy rating on Novadaq Technologies (NASDAQ: NVDQ) and increased its price target from $11 to $13.25.
Taglich Brothers commented, "Reconstructive, cardiac and urological surgery markets have been penetrated to an extent that has made Novadaq cash flow positive. Novadaq aims to commercialize, on its own, the PINPOINT endoscopic imaging systems for minimally invasive surgeries. Substantial development costs for PINPOINT will continue to burn cash through next year. But fortified with $37 million in proceeds from a common stock offering, Novadaq is well prepared for expanded product development and penetration of additional large markets."
Taglich Brothers closed at $9.11 on Wednesday.
Latest Ratings for NVDQ
|Jan 2016||JMP Securities||Initiates Coverage on||Market Outperform|
|Oct 2015||First Analysis||Upgrades||Equal-weight||Overweight|
|Oct 2015||Canaccord Genuity||Maintains||Buy|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.